Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 16/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120821 | 0.95 | ITGB3 (0.68) | ITGB3ITGA2BCYP3A4HIF1A | |
| SCHEMBL7013890 | 0.91 | ITGB3 (0.76) | ITGB3ITGA2BCYP2C9TSHRCYP3A4 | |
| SCHEMBL7008591 | 0.87 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7149518 | 0.85 | ITGB3 (0.67) | ITGB3ITGA2BCYP2C9CYP3A4CYP2D6 | |
| SCHEMBL7009478 | 0.81 | ITGB3 (0.89) | ITGB3ITGA2B | |
| SCHEMBL7010015 | 0.81 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7012381 | 0.77 | ITGB3 (0.73) | ITGB3ITGA2BCYP2C9TSHRCYP3A4 | |
| SCHEMBL7016388 | 0.75 | ITGB3 (0.77) | ITGB3ITGA2BCYP2C9TSHRCYP3A4 | |
| SCHEMBL7015728 | 0.75 | ITGB3 (0.88) | ITGB3ITGA2B | |
| SCHEMBL7118287 | 0.73 | ITGB3 (0.74) | ITGB3ITGA2BCYP2C9TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | ITGB3 139/4885ITGA2B 90/4885CYP2C9 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.